Hepatitis Monthly

Published by: Kowsar

YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy

Rahim Rahimi 1 , Seyed Younes Hosseini 2 , Mohammad Reza Fattahi 2 , * , Masood Sepehrimanesh 2 , Alireza Safarpour 2 , Seyed Ali Malekhosseini 3 , Maryam Nejabat 2 , 4 , Mahboobeh Khodadad 2 and Maryam Ardebili 2 , 5
Authors Information
1 Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, IR Iran
5 National Research Institute for Science Policy Tehran, IR Iran
Article information
  • Hepatitis Monthly: July 01, 2015, 15 (7); e27120
  • Published Online: July 22, 2015
  • Article Type: Research Article
  • Received: January 19, 2015
  • Revised: February 16, 2015
  • Accepted: May 10, 2015
  • DOI: 10.5812/hepatmon.27120v2

To Cite: Rahimi R, Hosseini S Y, Fattahi M R, Sepehrimanesh M, Safarpour A, et al. YMDD Motif Mutation Profile Among Patients Receiving Liver Transplant Due to Hepatitis B Virus Infection With Long Term Lamivudine/Immunoglobulin Therapy, Hepat Mon. 2015 ;15(7):e27120. doi: 10.5812/hepatmon.27120v2.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007; 81(8): 4215-25[DOI][PubMed]
  • 2. Mehrdad R, Farzaneh S, Shahab F, AminiBavil OS, Seyed Y, Hossein R, et al. Prediction of hepatitis B virus lamivudine resistance based on YMDD sequence data using an artificial neural network model. Hepat Mon. 2011; 11(2): 108-13
  • 3. Chen EQ, Bai L, Chen LL, Zhou TY, Du LY, Tang H. Prolonged Combination Therapy is More Effective than Monotherapy in Management of Chronic Hepatitis B Patients With Sustained Virological Response: An Experience From a 'Real-World' Clinical Setting. Iran Red Crescent Med J. 2013; 15(12)[DOI][PubMed]
  • 4. Alavian SM, Keyvani H, Rezai M, Ashayeri N, Sadeghi HM. Preliminary report of hepatitis B virus genotype prevalence in Iran. World J Gastroenterol. 2006; 12(32): 5211-3[PubMed]
  • 5. Ding X, Mizokami M, Ge X, Orito E, Iino S, Ueda R, et al. Different hepatitis B virus genotype distributions among asymptomatic carriers and patients with liver diseases in Nanning, southern China. Hepatol Res. 2002; 22(1): 37-44[PubMed]
  • 6. Sallam TA, William Tong CY. African links and hepatitis B virus genotypes in the Republic of Yemen. J Med Virol. 2004; 73(1): 23-8[DOI][PubMed]
  • 7. Saudy N, Sugauchi F, Tanaka Y, Suzuki S, Aal AA, Zaid MA, et al. Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. J Med Virol. 2003; 70(4): 529-36[DOI][PubMed]
  • 8. Yalcin K, Degertekin H, Bahcecioglu IH, Demir A, Aladag M, Yildirim B, et al. Hepatitis B virus genotype D prevails in patients with persistently elevated or normal ALT levels in Turkey. Infection. 2004; 32(1): 24-9[DOI][PubMed]
  • 9. Idrees M, Khan S, Riazuddin S. Common genotypes of hepatitis B virus. J Coll Physicians Surg Pak. 2004; 14(6): 344-7[PubMed]
  • 10. Yuan CH, Xiu DR, Jiang B, Li ZF, Li L, Song SB, et al. HBV recurrence lowered by lamivudine/HBIG combination therapy in liver transplant patients: ten-year experience. Hepatobiliary Pancreat Dis Int. 2013; 12(2): 149-53[PubMed]
  • 11. Wong TC, Fung JY, Lo CM. Prevention of recurrent hepatitis B infection after liver transplantation. Hepatobiliary Pancreat Dis Int. 2013; 12(5): 465-72[PubMed]
  • 12. Selcuk H, Karakayali H, Haberal M. Liver transplant and chronic hepatitis B virus infection. Exp Clin Transplant. 2011; 9(2): 94-7[PubMed]
  • 13. Amini-Bavil-Olyaee S, Hosseini SY, Sabahi F, Alavian SM. Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine. Int J Infect Dis. 2008; 12(1): 83-7[DOI][PubMed]
  • 14. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2005; 34 Suppl 1-3[PubMed]
  • 15. van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006; 44(2): 318-25[DOI][PubMed]
  • 16. van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004; 40(6): 1421-5[DOI][PubMed]
  • 17. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351(15): 1521-31[DOI][PubMed]
  • 18. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006; 44(3): 703-12[DOI][PubMed]
  • 19. Bui Han SH, Martin P. Liver transplantation for hepatitis B. Hepatol Res. 2004; 29(4): 193-201[DOI][PubMed]
  • 20. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the path forward? Drugs. 2000; 60(3): 517-31[PubMed]
  • 21. Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology. 2000; 32(5): 1145-53[DOI][PubMed]
  • 22. Hosseini SY, Sabahi F, Amini-Bavil-Olyaee S, Alavian SM, Merat S. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains. J Virol Methods. 2006; 137(2): 298-303[DOI][PubMed]
  • 23. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341(17): 1256-63[DOI][PubMed]
  • 24. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998; 339(2): 61-8[DOI][PubMed]
  • 25. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000; 119(1): 172-80[PubMed]
  • 26. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology. 1999; 29(5): 1581-6[DOI][PubMed]
  • 27. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology. 1998; 27(6): 1670-7[DOI][PubMed]
  • 28. Andreone P, Caraceni P, Grazi GL, Belli L, Milandri GL, Ercolani G, et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol. 1998; 29(6): 985-9[PubMed]
  • 29. Kamat SP, Mehta PR, Paranjpe SM, Ingole NA. Hepatitis B Virus (HBV) Infection in Liver Disease Patients in Mumbai, India with Special Reference to Hepatitis B Surface Antigen (HBsAg) Mutant Detection. J Clin Diagn Res. 2014; 8(3): 19-21[DOI][PubMed]
  • 30. Ezzatpanah Fard S, Sharifi Z, Hosseini SM, Mahmoodian Shooshtari M. The incidence of Drug- Resistant Mutants in Patients with Chronic HBV Infection After Lamivudine Treatment. Jundishapur J Microbiol. 2013; 6(8)[DOI]
  • 31. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology. 2001; 33(2): 424-32[DOI][PubMed]
  • 32. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, Yuen MF. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int. 2008; 28(10): 1408-16[DOI][PubMed]
  • 33. Karimi A, Salimzadeh L, Bagheri N. Hepatitis B Virus Genotyping Among Chronic Hepatitis B Individuals With Resistance to Lamivudine in Shahrekord, Iran. Jundishapur J Microbiol. 2014; 7(5)[DOI]
  • 34. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2004; 47(6): 289-309[DOI][PubMed]
  • 35. Amini-Bavil-Olyaee S, Sarrami-Forooshani R, Mahboudi F, Sabahi F, Adeli A, Noorinayer B, et al. Genotype characterization and phylogenetic analysis of hepatitis B virus isolates from Iranian patients. J Med Virol. 2005; 75(2): 227-34[DOI][PubMed]
  • 36. Amini-Bavil-Olyaee S, Sarrami-Forooshani R, Adeli A, Sabahi F, Abachi M, Azizi M, et al. Complete genomic sequence and phylogenetic relatedness of hepatitis B virus isolates from Iran. J Med Virol. 2005; 76(3): 318-26[DOI][PubMed]
  • 37. Thakur V, Sarin SK, Rehman S, Guptan RC, Kazim SN, Kumar S. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol. 2005; 24(1): 12-5[PubMed]
  • 38. Buti M, Jardi R, Rodriguez-Frias F, Valdes A, Schaper M, Esteban R, et al. Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy. Aliment Pharmacol Ther. 2005; 21(11): 1349-56[DOI][PubMed]
  • 39. Jardi R, Rodriguez F, Buti M, Costa X, Valdes A, Allende H, et al. Mutations in the basic core promoter region of hepatitis B virus. Relationship with precore variants and HBV genotypes in a Spanish population of HBV carriers. J Hepatol. 2004; 40(3): 507-14[DOI][PubMed]
  • 40. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001; 33(3): 751-7[DOI][PubMed]
  • 41. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol. 2013; 108(6): 942-8[DOI][PubMed]
  • 42. Gerlich WH. Diagnostic problems caused by HBsAg mutants-a consensus report of an expert meeting. Intervirology. 2004; 47(6): 310-3[PubMed]
  • 43. Zhang X, An Y, Jiang X, Xu M, Xu L, Chen S, et al. Entecavir versus Lamivudine therapy for patients with chronic hepatitis B-associated liver failure: a meta-analysis. Hepat Mon. 2014; 14(11)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments